Feature Type | Standardized | Nominal ANOVA | ||||
---|---|---|---|---|---|---|
mRNA | BRD-K11533227 | CTRPv2 | pan-cancer | AAC | -0.017 | 0.7 |
mRNA | NVP-231 | CTRPv2 | pan-cancer | AAC | -0.015 | 0.7 |
mRNA | FQI-2 | CTRPv2 | pan-cancer | AAC | 0.015 | 0.7 |
mRNA | XMD14-99 | GDSC1000 | pan-cancer | AAC | -0.015 | 0.7 |
mRNA | tivozanib | GDSC1000 | pan-cancer | AAC | 0.016 | 0.7 |
mRNA | AZ628 | GDSC1000 | pan-cancer | AAC | 0.022 | 0.7 |
mRNA | ruxolitinib | CTRPv2 | pan-cancer | AAC | -0.016 | 0.7 |
mRNA | B02 | CTRPv2 | pan-cancer | AAC | -0.016 | 0.7 |
mRNA | MPS-1-IN-1 | GDSC1000 | pan-cancer | AAC | 0.015 | 0.7 |
mRNA | BRD-K07442505 | CTRPv2 | pan-cancer | AAC | 0.017 | 0.7 |